# Boston Scientific Moat

Status: stale. Policy: company-analysis-1.

Boston Scientific has differentiated products, completed regulatory approvals and sustained demand, but the passages do not establish durable protection against competing devices and therapies. Intellectual property and physician familiarity support plausible moat mechanisms; their economic duration and customer dependence remain unproven. Competition affected Electrophysiology sales in 2026. Margins remained resilient, but realized pricing cannot be separated from volume and mix, while purchasing agreements constrain pricing discretion. This is insufficient evidence of a durable moat, rather than evidence of a broadly weak competitive position.

## intangible_assets

Current product differentiation is supported by Intracept's disclosed regulatory distinction, completed FARAPULSE indication approvals and product-led sales growth. WATCHMAN's global leadership is an issuer assertion. Patents and licenses support protection, but their existence alone does not establish a durable economic moat.

Durability: Regulatory development requirements and proprietary technology can delay replication. The catalog does not establish remaining exclusivity, competitor replication times or sustained product-level economic protection.

Risks: Electrophysiology competition already affected sales. Alternative therapies, patent circumvention, reimbursement changes and product discontinuation can erode differentiation. Abbott's disclosed PFA and mapping portfolio confirms overlapping competition without establishing relative clinical superiority.

Invalidation: The advantage would be undermined by comparable competing approvals followed by sustained share or pricing losses, loss of reimbursement for differentiated procedures, or invalidation or circumvention of commercially important proprietary rights.

Competitors: Abbott Laboratories, Medtronic plc
## switching_costs

Physician familiarity is a disclosed competitive factor and may support switching friction. Continued product demand is demonstrated indirectly by organic growth, but customer lock-in, retraining costs and repeat purchasing by the same institutions are not established.

Durability: Potential rather than a demonstrated durable advantage; no quantified switching burden or contractual customer dependence is supplied.

Risks: Clinical improvements and competing platforms can overcome familiarity. Consolidated purchasers and negotiated purchasing agreements may override physician preferences.

Invalidation: Evidence of institutions readily substituting competing platforms without meaningful retraining, workflow disruption or economic cost would invalidate the proposed switching-friction mechanism.

Competitors: Abbott Laboratories, Medtronic plc
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm) · 2026-02-17
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm) · 2026-08-03
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm) · 2026-03-18
- [https://www.sec.gov/Archives/edgar/data/885725/000088572525000011/bsx-20241231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572525000011/bsx-20241231.htm) · 2025-02-18
- [https://www.sec.gov/Archives/edgar/data/885725/000088572524000017/bsx-20231231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572524000017/bsx-20231231.htm) · 2024-02-20
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm) · 2026-05-01
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm) · 2026-07-29
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/q12026earningsrelease.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/q12026earningsrelease.htm) · 2026-04-22
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000013/boardappointmentspressrele.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000013/boardappointmentspressrele.htm) · 2026-02-23
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm) · 2026-10-07
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000061/bsx-20260921.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000061/bsx-20260921.htm) · 2026-09-23
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000036/bsx-20260430.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000036/bsx-20260430.htm) · 2026-05-05
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000013/bsx-20260218.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000013/bsx-20260218.htm) · 2026-02-23
- [https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm) · 2026-02-20
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm) · 2026-06-18

[JSON](https://beanvest.com/stock/bsx/moat.json)